Literature DB >> 2991605

Tissue selectivity of murine leukemia virus infection is determined by long terminal repeat sequences.

C A Rosen, W A Haseltine, J Lenz, R Ruprecht, M W Cloyd.   

Abstract

Here we show that the tissue specificity of murine retrovirus infections is determined by the long terminal repeat (LTR) of an otherwise isogenic set of viruses. The isogenic viruses used for this study contain the coding gag, pol, and env genes of the avirulent Akv virus. Recombinant viruses that contain the LTR of a virus that induces T-cell leukemia lymphoma preferentially infect T lymphocytes. Viruses that carry the LTR of a virus that induces erythroleukemia preferentially infect non-T lymphoblastoid cell lines in the marrow and spleen. The Akv virus itself displays no tissue preference for hematopoietic cells. These experiments suggest that retroviruses that carry appropriate enhancer-promoters can be used to infect selectively specific target cells in animals.

Entities:  

Mesh:

Year:  1985        PMID: 2991605      PMCID: PMC255076     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Novel leukaemogenic retroviruses isolated from cell line derived from spontaneous AKR tumour.

Authors:  F S Pedersen; R L Crowther; D Y Tenney; A M Reimold; W A Haseltine
Journal:  Nature       Date:  1981-07-09       Impact factor: 49.962

2.  Host-specific activation of transcription by tandem repeats from simian virus 40 and Moloney murine sarcoma virus.

Authors:  L A Laimins; G Khoury; C Gorman; B Howard; P Gruss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

3.  Characterization of enhancer elements in the long terminal repeat of Moloney murine sarcoma virus.

Authors:  L A Laimins; P Gruss; R Pozzatti; G Khoury
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

4.  Suppression of leukaemia virus pathogenicity by polyoma virus enhancers.

Authors:  B Davis; E Linney; H Fan
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

5.  Molecular analysis of the envelope gene and long terminal repeat of Friend mink cell focus-inducing virus: implications for the functions of these sequences.

Authors:  W Koch; W Zimmermann; A Oliff; R Friedrich
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

6.  A new class of murine leukemia virus associated with development of spontaneous lymphomas.

Authors:  J W Hartley; N K Wolford; L J Old; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

7.  A 3' end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus.

Authors:  P A Chatis; C A Holland; J E Silver; T N Frederickson; N Hopkins; J W Hartley
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

8.  Role for the 3' end of the genome in determining disease specificity of Friend and Moloney murine leukemia viruses.

Authors:  P A Chatis; C A Holland; J W Hartley; W P Rowe; N Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

9.  Thymotropism of murine leukemia virus is conferred by its long terminal repeat.

Authors:  L DesGroseillers; E Rassart; P Jolicoeur
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

10.  Construction and isolation of a transforming murine retrovirus containing the src gene of Rous sarcoma virus.

Authors:  S M Anderson; E M Scolnick
Journal:  J Virol       Date:  1983-05       Impact factor: 5.103

View more
  67 in total

1.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Differential DNA binding of nuclear proteins to a long terminal repeat region of the MCF13 and Akv murine leukemia viruses.

Authors:  F K Yoshimura; J Tupper; K Diem
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

3.  Loss of pathogenicity of spleen focus-forming virus after pseudotyping with Akv.

Authors:  K S Jones; S Ruscetti; F Lilly
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

4.  Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors.

Authors:  M L Mucenski; B A Taylor; J N Ihle; J W Hartley; H C Morse; N A Jenkins; N G Copeland
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

5.  SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.

Authors:  B Hallberg; J Schmidt; A Luz; F S Pedersen; T Grundström
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

6.  Different relative expression from two murine leukemia virus long terminal repeats in unintegrated transfected DNA and in integrated retroviral vector proviruses.

Authors:  K Paludan; H Y Dai; M Duch; P Jørgensen; N O Kjeldgaard; F S Pedersen
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  Antigenic subclasses of polytropic murine leukemia virus (MLV) isolates reflect three distinct groups of endogenous polytropic MLV-related sequences in NFS/N mice.

Authors:  Leonard H Evans; Marc Lavignon; Marc Taylor; A S M Alamgir
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy.

Authors:  J G Julias; D Hash; V K Pathak
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Pathogenic determinants in the U3 region of recombinant murine leukemia viruses isolated from CWD and HRS/J mice.

Authors:  S C Lawrenz-Smith; A C Massey; D J Innes; C Y Thomas
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Virological events leading to spontaneous AKR thymomas.

Authors:  J P Stoye; C Moroni; J M Coffin
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.